BR112014029149A2 - biomateriais adequados para uso como implantes eluíveis por fármacos e detectáveis por ressonância magnética para oclusão vascular - Google Patents

biomateriais adequados para uso como implantes eluíveis por fármacos e detectáveis por ressonância magnética para oclusão vascular

Info

Publication number
BR112014029149A2
BR112014029149A2 BR112014029149A BR112014029149A BR112014029149A2 BR 112014029149 A2 BR112014029149 A2 BR 112014029149A2 BR 112014029149 A BR112014029149 A BR 112014029149A BR 112014029149 A BR112014029149 A BR 112014029149A BR 112014029149 A2 BR112014029149 A2 BR 112014029149A2
Authority
BR
Brazil
Prior art keywords
implants
drug
magnetic resonance
vascular occlusion
eluting
Prior art date
Application number
BR112014029149A
Other languages
English (en)
Inventor
Chaix Celine
Thomas Meriadeg
Reb Philippe
Original Assignee
Biosphere Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosphere Medical Inc filed Critical Biosphere Medical Inc
Publication of BR112014029149A2 publication Critical patent/BR112014029149A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1854—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

resumo "biomateriais adequados para uso como implantes eluíveis por fármacos e detectáveis por ressonância magnética para oclusão vascular" trata-se de biomateriais adequados para uso como implantes eluíveis por fármacos e detectáveis por ressonância magnética ("irm") para oclusão vascular são fornecidos, bem como métodos de produzir tais biomateriais. adicionalmente, são fornecidos métodos de tratamento de um indivíduo acometido por um tumor sólido.
BR112014029149A 2012-05-24 2013-05-23 biomateriais adequados para uso como implantes eluíveis por fármacos e detectáveis por ressonância magnética para oclusão vascular BR112014029149A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261651389P 2012-05-24 2012-05-24
PCT/US2013/042363 WO2013177364A1 (en) 2012-05-24 2013-05-23 Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion

Publications (1)

Publication Number Publication Date
BR112014029149A2 true BR112014029149A2 (pt) 2017-06-27

Family

ID=49621771

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029149A BR112014029149A2 (pt) 2012-05-24 2013-05-23 biomateriais adequados para uso como implantes eluíveis por fármacos e detectáveis por ressonância magnética para oclusão vascular

Country Status (7)

Country Link
US (1) US10695440B2 (pt)
EP (2) EP3295961B1 (pt)
JP (1) JP6208749B2 (pt)
BR (1) BR112014029149A2 (pt)
CA (1) CA2866896C (pt)
ES (1) ES2655656T3 (pt)
WO (1) WO2013177364A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3295961B1 (en) 2012-05-24 2020-04-08 Biosphere Medical Inc. Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion
JP6405369B2 (ja) 2013-09-19 2018-10-17 テルモ株式会社 ポリマー粒子
BR112016005768B1 (pt) 2013-09-19 2021-09-21 Microvention, Inc Películas de polímero
KR102287781B1 (ko) 2013-11-08 2021-08-06 테루모 가부시키가이샤 중합체 입자
US9907880B2 (en) 2015-03-26 2018-03-06 Microvention, Inc. Particles
US10328175B2 (en) 2016-09-28 2019-06-25 Terumo Corporation Polymer particles

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS509858A (pt) 1973-06-02 1975-01-31
JPS6056676B2 (ja) 1980-07-18 1985-12-11 日立造船株式会社 コンクリ−ト複合パネル
ATE130517T1 (de) 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
FR2676927B1 (fr) 1991-05-29 1995-06-23 Ibf Microspheres utilisables pour les occlusions vasculaires therapeutiques et solutions injectables les contenant.
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US6315709B1 (en) 1998-08-07 2001-11-13 Stereotaxis, Inc. Magnetic vascular defect treatment system
US8697137B2 (en) 2000-03-24 2014-04-15 Biosphere Medical, Inc. Methods of using microspheres for active embolization
FR2808026B1 (fr) * 2000-04-25 2002-06-14 Alexandre Laurent Biomateriau a base de polymere hydrophile presentant un signal specifique en imagerie par resonance magnetique et procede de preparation d'un tel biomateriau
JP2005053707A (ja) 2001-07-30 2005-03-03 Kankyo Device Kenkyusho:Kk 可視光応答性材料の製造方法
US7462366B2 (en) * 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US8012454B2 (en) * 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US20040161466A1 (en) * 2003-02-14 2004-08-19 Biocompatibles Uk Limited Chemoembolisation
EP1605922A4 (en) * 2003-03-24 2011-03-16 Biosphere Medical Inc TEMPORARY EMBOLIZATION USING REVERSIBLE THERMOSENSIVE POLYMERS WITH MOMENTARY ACTION
WO2005044224A2 (en) 2003-05-02 2005-05-19 Case Western Reserve University Drug delivery system based on polymer nanoshells
EP2143740B1 (en) * 2004-08-19 2013-06-19 Covidien LP Water-swellable copolymers and articles and coating made therefrom
US20110104052A1 (en) * 2007-12-03 2011-05-05 The Johns Hopkins University Methods of synthesis and use of chemospheres
GB0807154D0 (en) * 2008-04-18 2008-05-21 Univ Aston Intervertebral disc
WO2010138702A1 (en) * 2009-05-28 2010-12-02 Corning Incorporated Swellable synthetic microcarriers for culturing cells
WO2011003902A2 (en) * 2009-07-07 2011-01-13 Soenke Bartling Multimodal visible polymer embolization material
EP3295961B1 (en) 2012-05-24 2020-04-08 Biosphere Medical Inc. Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion

Also Published As

Publication number Publication date
US10695440B2 (en) 2020-06-30
EP3295961A1 (en) 2018-03-21
EP2854869A1 (en) 2015-04-08
CA2866896C (en) 2021-01-26
EP2854869B1 (en) 2017-11-01
EP2854869A4 (en) 2015-12-30
CA2866896A1 (en) 2013-11-28
US20130315838A1 (en) 2013-11-28
ES2655656T3 (es) 2018-02-21
WO2013177364A1 (en) 2013-11-28
EP3295961B1 (en) 2020-04-08
JP2015517390A (ja) 2015-06-22
JP6208749B2 (ja) 2017-10-04

Similar Documents

Publication Publication Date Title
BR112014029149A2 (pt) biomateriais adequados para uso como implantes eluíveis por fármacos e detectáveis por ressonância magnética para oclusão vascular
CY1118105T1 (el) Αγγειογενεση χρησιμοποιωντας πλακουντιακα βλαστικα κυτταρα
MX2015012933A (es) Micrordenamiento para suministro de agente terapeutico y metodos de uso.
MX359769B (es) Metodos para descelularizar huesos.
SG195194A1 (en) Nanogels
MX365521B (es) Polimeros que contienen zwiteriones de alto peso molecular.
CR20150217A (es) Inhibidores de histona demetilasas
CL2010000691A1 (es) Sistemas, dispositivos y/o metodos para gestionar cojinetes magneticos.
MX2013008437A (es) Marcadores de formacion de imagen por resonancia magnetica, sistemas de suministro y extraccion, y metodos de fabricacion y uso de los mismos.
GB201113856D0 (en) Medical device
BR112017001049A2 (pt) material biocomposto anisotrópico, implantes médicos contendo o mesmo e métodos de tratamento do mesmo
EA201391602A1 (ru) Контролируемое высвобождение иммунодепрессантов из синтетических наноносителей
EP2811939A4 (en) METHOD AND USES OF BIOLOGICAL TISSUE FOR DIFFERENT STENTS AND OTHER MEDICAL APPLICATIONS
IN2014DN10161A (pt)
MX351598B (es) Sistemas y métodos para determinar la compatibilidad de un implante para un procedimiento médico especifico.
CL2012003385A1 (es) Tratamiento para la incontinencia.
SG11201506260WA (en) Biodegradable metallic medical implants, method for preparing and use thereof
UY34539A (es) Heteroarilos y usos de los mismos
PH12015501088A1 (en) Dimeric compounds
MY172699A (en) Implantable medical devices with increased immune tolerance, and methods for making and implanting
DE112013005823A5 (de) Spule zur induktiven transkutanen Energie- und/oder Datenübertragung für aktive medizinische Implantate
PE20131065A1 (es) Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
MX365403B (es) Peptidos y metodos para usarlos.
IN2014DN10765A (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.